Skip to content

Use of Blood Ketone Meters to Improve Ambulance Hyperglycaemia Care

Use of Capillary Blood Ketone Meters to Improve Ambulance Service Care of Hyperglycaemic Patients: a Feasibility Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04940897
Acronym
KARMA2
Enrollment
420
Registered
2021-06-28
Start date
2021-10-25
Completion date
2023-02-23
Last updated
2023-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Ketoacidosis

Brief summary

In this KARMA2 feasibility study the investigators are testing whether ambulance staff can reliably and safely identify patients at high risk of diabetic ketoacidosis using blood ketone meters and start fluid (saline) therapy before arriving at hospital. The investigators aim to include 800 patients in this stepped wedge control study and the results will help decide if a larger study is warranted.

Detailed description

Diabetic ketoacidosis (DKA) is a potentially life-threatening condition which requires immediate treatment. National Health Service (NHS) hospital guidelines recommend immediate fluid (saline) therapy. Delays in diagnosis and treatment are known to be associated with health complications and death. There is an opportunity to involve ambulance crews to improve DKA identification and treatment times; however, currently ambulance staff do not have access to ketone testing, and fluids are recommended only when it is thought a patient is critically unwell. In this KARMA2 feasibility study the investigators are testing whether ambulance staff can reliably and safely identify patients at high risk of DKA using blood ketone meters and start fluid (saline) therapy before arriving at hospital. During an 8-month period (4-month control followed by 4-month intervention), 120 ambulance clinicians from the East of England Ambulance Service NHS Trust will receive training to consent 400 patients with hyperglycaemia and unwell patients with diabetes to the control group receiving usual care, followed by determining the presence of ketones using capillary blood testing from a further 400 consenting patients with hyperglycaemia and unwell patients with diabetes. Subsequent patient care will depend on the ketone value obtained: high-risk DKA patients will receive fluid therapy. Twenty ambulance and hospital clinicians will be invited to an online interview to share views of DKA care and the impact of ambulance blood ketone meters. The results will help the investigators decide if a larger study would be a good idea.

Interventions

OTHERUse of CareSens ketone meter

Use of CareSens ketone meter to identify blood ketone levels and delivery of fluid therapy to those patients at high risk of DKA

Sponsors

East of England Ambulance Service NHS Trust
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Stepped wedge control trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Aged 18 years or more * Attended by study clinician * Informed or Proxy consent to participate * Blood glucose level greater than 11mmol/L or unwell with history of diabetes * If required will be transported to partner hospital

Exclusion criteria

* Failure to meet inclusion criteria * Previously recruited to study

Design outcomes

Primary

MeasureTime frameDescription
Measure incidence of hyperglycaemia in study population18 monthsFrequency count of capillary blood glucose level greater than 11mmol/L
Measure incidence of diabetic ketoacidosis (DKA) in study population18 monthsFrequency count of capillary blood ketone level equal to or greater than 3mmol/L
Completeness of data capture by study clinicians18 monthsProgression criteria requires full record completion for a minimum of 70 percent of participants
Measure incidence of adverse eventsMaximum 18 monthsProgression criteria requires adverse event rate to be less than 1 percent of participants

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026